17,000 Cancer Cases: What the Four-Canton Register Really Shows
The new annual report cites around 17,000 diagnoses and nearly 3,700 cancer deaths in Zurich, Zug, Schaffhausen and Schwyz. What matters is how the figures are counted and put in context.
Around 17,000 new cancer cases and nearly 3,700 deaths from cancer: these are the orders of magnitude with which the joint register for Zurich, Zug, Schaffhausen and Schwyz describes the year 2025. The figures are striking. But they are not simple proof that cancer has suddenly become more common in the region. Anyone who wants to use the report for policy and care must distinguish between case numbers, incidence rates and data quality.
Together, the four cantons account for a large and growing share of the Swiss population. For that reason alone, the absolute number of diagnoses can rise even if the age-adjusted risk remains stable. Ageing adds to this: cancer occurs predominantly in older age groups. For a clean comparison over time, rates per 100,000 inhabitants and standardisation by age therefore matter more than the bare total.
A figure for care planning, not for personal prognoses
The 17,000 cases show above all how large the task is for hospitals, medical practices, pathology departments, cancer centres and follow-up care services. Every registered case generates diagnostics, treatment decisions and often years of care. The number is therefore useful as a planning figure: cantons can estimate where capacities, early detection or specialised services are lacking.
For an individual, it says far less. Personal risk depends on factors including age, sex, tumour type, hereditary factors and avoidable risks. “Cancer case” is not a uniform medical category either. An early-detected melanoma and an advanced lung cancer are both counted, but they differ greatly in treatment and prognosis.
Why register figures take time
Cancer registers do not simply take a finished list from the hospitals. Reports from medical practices, laboratories and institutions must be assigned to a person and a tumour, checked for duplicate reports and coded according to binding rules. Causes of death and later clinical information sometimes arrive with a delay. Earlier data versions are therefore updated on a regular basis.
Since 1 January 2020, the federal Cancer Registration Act has obliged physicians, hospitals, laboratories and other healthcare institutions to report certain data. At the same time, patients have a right to information and a right to object. Standardisation improves comparability between cantons but does not eliminate every gap. Missing or delayed reports can shift analyses; changes in recording practice can create apparent trends.
A look back shows this: for the incidence year 2022, the four-canton register recorded 8,489 new malignant cases in Zurich, 716 in Zug, 543 in Schaffhausen and 949 in Schwyz – in each case excluding non-melanoma skin cancer. Separate in-situ and borderline cases were reported alongside these. Which diagnoses are included in an overall total must therefore always be read along with it.
The national comparison prevents wrong conclusions
For the period 2018 to 2022, the Federal Statistical Office reports an annual average of around 26,500 new cases among men and 21,600 among women. These national estimates are based on the cantonal registers and exclude non-melanoma skin cancer. The age-standardised rates rose only slightly compared with 2013 to 2017. Cancer mortality fell over the long term in both sexes.
This produces a differentiated picture: the number of people treated can increase because of population growth and ageing, while individual risk barely rises and mortality falls for several tumour types. Conversely, stable overall rates can conceal problems with individual types of cancer. Register data only become informative through breakdowns by tumour type, age, sex, stage and region.
What the cantons can do with this
The real value of the annual report lies not in an alarming headline but in repeatable measurement. If diagnosis stage, start of treatment and survival are recorded consistently, gaps in care can be identified: for instance late diagnoses in certain population groups or regional differences in access to specialised centres. Such findings must, however, be verified; a register shows correlations, not automatically their causes.
For the four cantons, the task is therefore twofold: they must cope with the rising absolute burden on care and at the same time make data quality visible. Only if definitions, data status and uncertainties are disclosed does 17,000 individual cases become more than a large number – namely a solid basis for prevention and treatment.
